Alnylam Pharmaceuticals, Inc.
ALNY · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $30,037,557 | $23,908,257 | $28,919,391 | $20,086,921 |
| - Cash | $966,428 | $812,688 | $866,394 | $819,975 |
| + Debt | $1,296,048 | $1,305,387 | $1,320,248 | $997,592 |
| Enterprise Value | $30,367,177 | $24,400,956 | $29,373,245 | $20,264,538 |
| Revenue | $2,248,243 | $1,828,292 | $1,037,418 | $844,287 |
| % Growth | 23% | 76.2% | 22.9% | – |
| Gross Profit | $1,924,873 | $1,517,886 | $868,601 | $704,143 |
| % Margin | 85.6% | 83% | 83.7% | 83.4% |
| EBITDA | -$178,847 | -$258,242 | -$926,557 | -$661,556 |
| % Margin | -8% | -14.1% | -89.3% | -78.4% |
| Net Income | -$278,157 | -$440,242 | -$1,131,156 | -$852,824 |
| % Margin | -12.4% | -24.1% | -109% | -101% |
| EPS Diluted | -2.18 | -3.52 | -9.3 | -7.2 |
| % Growth | 38.1% | 62.2% | -29.2% | – |
| Operating Cash Flow | -$8,312 | $104,156 | -$541,274 | -$641,693 |
| Capital Expenditures | -$34,277 | -$62,211 | -$72,059 | -$76,372 |
| Free Cash Flow | -$42,589 | $41,945 | -$613,333 | -$718,065 |